Stock comparison
Halozyme Therapeutics
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 71B | HALO |
| Benjamin Graham | 83A | 76B | HALO |
| Philip Fisher | 65B | 76B | UTHR |
| Peter Lynch | 53D | 62C | UTHR |
| Joel Greenblatt | 40D | 46D | UTHR |
| Charlie Munger | 80C | 64C | HALO |
| Terry Smith | 84A | 64C | HALO |
Side-by-side metrics
| Metric | HALO | UTHR |
|---|---|---|
| Market cap | $8.1B | $24.13B |
| P/E (TTM) | 24.0x | 19.2x |
| EV/EBIT | 10.2x | 15.2x |
| ROIC (TTM) | 23.65% | 18.81% |
| Gross margin | 81.24% | 86.58% |
| Net margin | 23.13% | 40.61% |
| Revenue CAGR 5y | 33.23% | 17.22% |
| EPS CAGR 5y | -1.98% | 29.84% |
| Debt / Equity | 1.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 17.22%+48%
- EV/EBIT10.2xvs 15.2x+33%
- ROIC (TTM)23.65%vs 18.81%+20%
UTHR leads on
- EPS CAGR 5y29.84%vs -1.98%+107%
- Debt / Equity-vs 1.0x+100%
- Market cap$24.13Bvs $8.1B+66%
- Net margin40.61%vs 23.13%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.